Assertio Therapeutics, Inc. (ASRT) Analysts See $-0.30 EPS; Profile of 7 Analysts Covering ONEOK, Inc. (OKE)


Among 12 analysts covering ONEOK (NYSE:OKE), 7 have Buy rating, 0 Sell and 5 Hold. Therefore 58% are positive. ONEOK had 13 analyst reports since September 13, 2018 according to SRatingsIntel. JP Morgan upgraded the stock to “Overweight” rating in Tuesday, January 8 report. The firm has “Buy” rating by Bank of America given on Friday, November 2. Jefferies upgraded ONEOK, Inc. (NYSE:OKE) rating on Tuesday, October 16. Jefferies has “Buy” rating and $77 target. On Tuesday, January 8 the stock rating was downgraded by Bernstein to “Market Perform”. The rating was maintained by Wells Fargo on Thursday, November 1 with “Outperform”. The company was upgraded on Thursday, November 29 by Citigroup. Wells Fargo maintained ONEOK, Inc. (NYSE:OKE) on Thursday, September 13 with “Outperform” rating. The rating was downgraded by Barclays Capital on Friday, October 12 to “Equal-Weight”. See ONEOK, Inc. (NYSE:OKE) latest ratings:

18/01/2019 Broker: SunTrust Rating: Buy New Target: $72 Initiates Coverage On
11/01/2019 Broker: Raymond James Rating: Strong Buy Initiates Coverage On
08/01/2019 Broker: Bernstein Old Rating: Outperform New Rating: Market Perform Downgrade
08/01/2019 Broker: JP Morgan Old Rating: Neutral New Rating: Overweight Old Target: $75 New Target: $74 Upgrade
29/11/2018 Broker: Mizuho Rating: Neutral New Target: $70 Initiates Coverage On
29/11/2018 Broker: Citigroup Old Rating: Neutral New Rating: Buy New Target: $67 Upgrade
02/11/2018 Broker: Bank of America Old Rating: Neutral New Rating: Buy Old Target: $71 New Target: $75 Upgrade
01/11/2018 Broker: Wells Fargo Old Rating: Outperform New Rating: Outperform Old Target: $75 New Target: $76 Maintain
16/10/2018 Broker: Jefferies Old Rating: Hold New Rating: Buy New Target: $77 Upgrade
12/10/2018 Broker: Barclays Capital Old Rating: Overweight New Rating: Equal-Weight Old Target: $73 New Target: $70 Downgrade

Analysts expect Assertio Therapeutics, Inc. (NASDAQ:ASRT) to report $-0.30 EPS on February, 26.They anticipate $0.08 EPS change or 21.05% from last quarter’s $-0.38 EPS. After having $0.65 EPS previously, Assertio Therapeutics, Inc.’s analysts see -146.15% EPS growth. The stock decreased 0.70% or $0.03 during the last trading session, reaching $4.28. About 807,877 shares traded. Assertio Therapeutics, Inc. (NASDAQ:ASRT) has declined 48.98% since February 14, 2018 and is downtrending. It has underperformed by 48.98% the S&P500.

Investors sentiment decreased to 1.16 in 2018 Q3. Its down 0.17, from 1.33 in 2018Q2. It worsened, as 36 investors sold ONEOK, Inc. shares while 217 reduced holdings. 89 funds opened positions while 204 raised stakes. 289.04 million shares or 1.67% less from 293.95 million shares in 2018Q2 were reported. Kbc Grp Inc Nv holds 0.03% or 52,128 shares in its portfolio. Moreover, Mariner Wealth has 0.13% invested in ONEOK, Inc. (NYSE:OKE) for 34,165 shares. California State Teachers Retirement Sys has 779,832 shares. Tiedemann Advisors Llc accumulated 106,397 shares. Moreover, Korea Investment has 0.01% invested in ONEOK, Inc. (NYSE:OKE). Dana Inv Advsr accumulated 358,100 shares or 0.99% of the stock. Duff Phelps Inv Mngmt accumulated 455,421 shares. Andra Ap owns 70,200 shares or 0.12% of their US portfolio. Fjarde Ap has 0.11% invested in ONEOK, Inc. (NYSE:OKE) for 113,011 shares. The New York-based Tiaa Cref Investment Mgmt Limited Liability Com has invested 0.05% in ONEOK, Inc. (NYSE:OKE). First Dallas Securities Inc stated it has 1.45% of its portfolio in ONEOK, Inc. (NYSE:OKE). Mirae Asset Global Invests Ltd has invested 0.3% in ONEOK, Inc. (NYSE:OKE). Teachers Retirement Of The State Of Kentucky holds 40,800 shares or 0.03% of its portfolio. Karpas Strategies Limited Liability, New York-based fund reported 80,422 shares. Lord Abbett Com Ltd Liability Corporation has invested 0.17% in ONEOK, Inc. (NYSE:OKE).

The stock increased 1.33% or $0.87 during the last trading session, reaching $66.08. About 1.90M shares traded. ONEOK, Inc. (NYSE:OKE) has risen 12.88% since February 14, 2018 and is uptrending. It has outperformed by 12.88% the S&P500. Some Historical OKE News: 01/05/2018 – ONEOK MAINTAINS 2018 FINL GUIDANCE; 19/04/2018 – ONEOK BOOSTS QTR DIV TO 79.5C/SHR FROM 77C, EST. 79C; 17/04/2018 – ONEOK INC OKE.N : SEAPORT GLOBAL STARTS WITH NEUTRAL, $60 TARGET PRICE; 19/04/2018 – ONEOK BOOSTS QTRLY DIV; 04/04/2018 – IGNORE: ONEOK REPORTED EDI SERVICES SUSPENSION APRIL 3; 03/04/2018 – OKE: NO OPERATIONAL INTERRUPTIONS ON NATURAL GAS PIPELINES; 03/04/2018 – Oneok: No Operational Interruptions on Oneok’s Pipelines; 16/03/2018 – Oneok Inc Closes Above 50-Day Moving Average: Technicals; 04/04/2018 – ONEOK TEMPORARILY DISABLES ELECTRONIC DATA INTERCHANGE SERVICES; 03/05/2018 – ONEOK INC OKE.N : DEUTSCHE BANK RAISES TARGET PRICE TO $65 FROM $62

More important recent ONEOK, Inc. (NYSE:OKE) news were published by: which released: “ONEOK Investors Have 6 Billion Reasons to Be Excited About What’s Ahead – The Motley Fool” on January 31, 2019, also published article titled: “Why These 4 Midstream Players Jumped Double Digits in January – Motley Fool”, published: “Report: Developing Opportunities within ONEOK, Alaska Air Group, Comcast, Mack-Cali Realty, Vistra Energy, and Xencor — Future Expectations, Projections Moving into 2019 – GlobeNewswire” on January 28, 2019. More interesting news about ONEOK, Inc. (NYSE:OKE) was released by: and their article: “RBC Global Energy Best Ideas Up Big in 2019: 4 to Buy Now – 24/7 Wall St.” with publication date: February 06, 2019.

ONEOK, Inc., through its general partner interests in ONEOK Partners, L.P., engages in the gathering, processing, storage, and transportation of natural gas in the United States. The company has market cap of $27.18 billion. It operates through Natural Gas Gathering and Processing, Natural Gas Liquids, and Natural Gas Pipelines divisions. It has a 29.29 P/E ratio. It owns natural gas gathering pipelines and processing plants in the Mid-Continent and Rocky Mountain regions.

Assertio Therapeutics, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. The company has market cap of $273.66 million. It offers Gralise , an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults. It has a 9.73 P/E ratio. The firm also provides NUCYNTA ER (tapentadol extended release tablet), a product for the management of pain severe enough to long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults; and NUCYNTA IR (tapentadol), a product for the management of moderate to severe acute pain in adults.

ONEOK, Inc. (NYSE:OKE) Institutional Positions Chart